Insmed stock price drops due to failure of hidradenitis suppurativa trial

Investing.com – Insmed Incorporated (Nasdaq stock ticker: INSM) shares fell 2% in after-hours trading on Tuesday, after the company said it will discontinue its hidradenitis suppurativa program following a failed Phase 2b clinical trial.

The CEDAR study assessed the efficacy of brensocatib in adult patients with moderate to severe hidradenitis suppurativa, but neither the 10 mg nor the 40 mg treatment groups met the primary or secondary efficacy endpoints. The company said it will discontinue the development of brensocatib in the hidradenitis suppurativa space.

At Week 16, the total number of abscesses and inflammatory nodules among participants in the 10 mg and 40 mg treatment groups decreased by 45.5% and 40.3%, respectively, versus 57.1% in the placebo group. The improvement in the placebo group outperformed both treatment groups.

Brensocatib was well tolerated, with no new safety signals identified, including in the 40 mg treatment group, which is the highest dose studied by Insmed to date. During the 16-week placebo-controlled treatment period, 55.4% of patients in the 10 mg treatment group experienced treatment-emergent adverse events, 42.9% of patients in the 40 mg treatment group experienced treatment-emergent adverse events, while the figure was 45.7% in the placebo group.

The CEDAR study is a randomized, double-blind, placebo-controlled Phase 2b clinical trial that enrolled 214 patients across 72 research sites worldwide. Participants were randomized to receive brensocatib 10 mg, brensocatib 40 mg, or placebo once daily for 16 weeks.

Insmed plans to present these data at future academic conferences. The company said that clinical development for hidradenitis suppurativa faces especially significant challenges due to a lack of established animal models.

This article was translated with the assistance of artificial intelligence. For more information, please see our Terms of Use.